Clinical Trials About "Sarah's Pastries and Candies" RSS

03:06 EDT 20th October 2017 | BioPortfolio

We list hundreds of Clinical Trials about "Sarah's Pastries and Candies" on BioPortfolio. We draw our references from global clinical trials data listed on and refresh our database daily.

More Information about "Sarah's Pastries and Candies" on BioPortfolio

We have published hundreds of Sarah's Pastries and Candies news stories on BioPortfolio along with dozens of Sarah's Pastries and Candies Clinical Trials and PubMed Articles about Sarah's Pastries and Candies for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sarah's Pastries and Candies Companies in our database. You can also find out about relevant Sarah's Pastries and Candies Drugs and Medications on this site too.

Showing "Sarah Pastries Candies" Clinical Trials, all 4



Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type,...

Probably Relevant

The RECHARGE Low Carbohydrate Diet Trial for Metastatic Cancer

This study is for people whose cancer: - has resisted chemotherapy - are taking a break from chemotherapy - or are looking for an alternative to the toxic effects of chemotherapy The trial is looking to see if a very low carbohydrate diet can inhibit the growth of certain cancers. The two major goals of the RECHARGE study are to determine: - whether a very low carbohydrate diet can help participants reduce the amount of cancer in their b...

Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer

In this study, patients with metastatic HER2-negative breast cancer will receive treatment with ixabepilone and sorafenib until disease progression or unacceptable toxicity occurs. The Phase I portion of this study will determine the maximum tolerated doses (MTDs) of sorafenib and ixabepilone that may be used in combination for first- or second-line treatment of MBC. The MTDs identified in the Phase I portion of the study will be used in the Phase II portion which will evaluat...

Possibly Relevant

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Treatment of triple negative breast cancer (TNBC) relies heavily on different regimes of chemotherapeutic agents but remains one of the most challenging subtypes to treat because of the lack of specific therapies. Despite being sensitive to chemotherapy, many women with TNBC relapse quickly, developing locoregional recurrence or visceral metastasis. Toxicity and chemotherapy resistance are still major limitations in the treatment of patients with TNBC. Despite current trend of ...

More From BioPortfolio on "Sarah's Pastries and Candies"

Quick Search